GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer

Published:2019-04-18 Issue:7 Volume:17 Page:1503-1518
ISSN:1541-7786
Container-title:Molecular Cancer Research
language:en
Short-container-title:Mol Cancer Res

Author:

Bevill Samantha M.,Olivares-Quintero Jose F.,Sciaky Noah,Golitz Brian T.,Singh Darshan,Beltran Adriana S.,Rashid Naim U.,Stuhlmiller Timothy J.,Hale Andrew^ORCID,Moorman Nathaniel J.,Santos Charlene M.,Angus Steven P.,Zawistowski Jon S.,Johnson Gary L.

Funder

HHS | National Institutes of HealthHHS | National Institutes of Health (NIH)

Susan G. Komen for the CureSusan G. Komen for the Cure (Susan G. Komen)

HHS | NIH | National Institute of General Medical SciencesHHS | NIH | National Institute of General Medical Sciences (NIGMS)

UNC University Cancer Research Fund

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology,Molecular Biology

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel inhibitors of bromodomain and extra-terminal domain trigger cell death in breast cancer cell lines;Bioorganic & Medicinal Chemistry;2024-10

2. BET inhibitors (BETi) influence oxidative phosphorylation metabolism by affecting mitochondrial dynamics leading to alterations in apoptotic pathways in triple‐negative breast cancer (TNBC) cells;Cell Proliferation;2024-09-02

3. Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines;PeerJ;2024-08-28

4. Chromatin remodellers as therapeutic targets;Nature Reviews Drug Discovery;2024-07-16

5. Analysis of serum peptidome profiles of non-metastatic and metastatic feline mammary carcinoma using liquid chromatography-tandem mass spectrometry;BMC Veterinary Research;2024-06-29